EP Patent

EP1452172A2 — Multiple unit pharmaceutical preparation

Assigned to AstraZeneca AB · Expires 2004-09-01 · 22y expired

What this patent protects

A new pharmaceutical multiple unit tableted dosage form containing as active substance an acid labile H + K + -ATPase inhibitor or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, a method for the manufacture of such a formulation, an…

USPTO Abstract

A new pharmaceutical multiple unit tableted dosage form containing as active substance an acid labile H + K + -ATPase inhibitor or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, a method for the manufacture of such a formulation, and the use of such a formulation in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
EP1452172A2
Jurisdiction
EP
Classification
—
Expires
2004-09-01
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.